Skip to main content
. 2022 Aug 17;6(16):4773–4781. doi: 10.1182/bloodadvances.2022007112

Figure 2.

Figure 2.

Laboratory responses. Cumulative incidence curves for time to normalization for anemia (A), hypoalbuminemia (B), thrombocytosis (C), CRP (D), IgG (E), and hyperfibrinogenemia (F) in patients treated with siltuximab or placebo. BSC, best supportive care.